Homology Medicines initiated with an Outperform at Evercore ISI. Evercore ISI analyst Ravi Mehrotra initiated Homology Medicines with an Outperform rating and a price targets of $29. The analyst says the company is “unique” within his gene therapy universe as it has “both gene therapy and gene editing capabilities using its proprietary AAVHSC vectors.” Mehrotra adds that the initial data from Homology Medicines’ lead program HMI-102 is expected in the second half of the year and “will help validate the company’s vectors.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.